Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 43547-346

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43547-346). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare U.s., Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clcr2 (13)

A formula calculating creatinine clearance (CLcr) based on age, weight, serum creatinine, and a factor for female patients. The formula divides the product of (140 minus age in years) and weight in kilograms by the product of 72 and serum creatinine in mg/dL, multiplied by 0.85 for female patients.*

FDA Label Image

Clcr2 (2)

A text panel showing a formula for adjusting creatinine clearance (CLcr) based on body surface area (BSA). It presents the calculation of adjusted CLcr (mL/min/1.73m²) by multiplying CLcr (mL/min) over BSA subject (m²) by 1.73.*

FDA Label Image

Levetiracetam Extended-release Structure (3)

Chemical structure of LEVETIRACETAM, showing a pyrrolidine ring with ethyl and carbamoylmethyl side groups.*

FDA Label Image

Figure 1 (4)

A bar chart comparing the percentage of patients achieving a defined outcome across three groups: placebo (7.4%, N=95), immediate-release levetiracetam 1000 mg/day (37.1%, N=97), and immediate-release levetiracetam 3000 mg/day (39.6%, N=101). Both levetiracetam groups show statistically significant improvement versus placebo, indicated by asterisks.*

FDA Label Image

Figure 2 (5)

A bar chart showing the percentage of patients in three groups: Placebo (111 patients) at 6.3%, Immediate-release levetiracetam tablets 1000 mg/day (106 patients) at 20.8%, and Immediate-release levetiracetam tablets 2000 mg/day (105 patients) at 35.2%. Statistically significant differences versus placebo are noted for both levetiracetam groups.*

FDA Label Image

Figure 3 (6)

A bar graph comparing the percentage of patients between placebo and immediate-release levetiracetam 3000 mg/day treatment groups. The placebo group (N=104) shows 14.4% of patients, while the immediate-release levetiracetam group (N=180) shows 39.4%, with a statistical significance indicated by an asterisk.*

FDA Label Image

Figure 4 (7)

A bar graph comparing the percentage of patients in two groups: placebo (19.6%) and immediate-release levetiracetam tablets (44.6%). The y-axis represents the percentage of patients from 0% to 45%. The graph includes a note marking the difference as statistically significant versus placebo.*

FDA Label Image

Image 01

Packaging label for Levetiracetam Extended-Release Tablets, USP 500 mg by Solco Healthcare U.S., LLC. The label indicates once-daily dosing, contains 60 film-coated extended-release tablets, and displays the NDC 43547-345-06. It includes storage instructions, manufacturer information, and a barcode.*

FDA Label Image

Image 02

The packaging label for Levetiracetam Extended-Release Tablets, USP, 750 mg, shows a box containing 60 film-coated, extended-release oral tablets. The label highlights once-daily dosing and directs pharmacists to dispense a separate medication guide. It indicates prescription use only and is labeled by Solco Healthcare U.S., LLC. The label includes storage instructions and manufacturer details from Zhejiang Huahai Pharmaceutical Co., Ltd.*

FDA Label Image

Image 03

Label for Levetiracetam Extended-Release Tablets, USP 500 mg by Solco Healthcare U.S., LLC. The label shows the product name, strength, and dosage form as film-coated extended-release tablets. It includes NDC 43547-345-06, a note for pharmacist to dispense a medication guide, and the package size of 60 tablets. Storage and manufacturing details are also visible.*

FDA Label Image

Image 04

Levetiracetam Extended-Release Tablets, USP 750 mg film-coated tablets, once-daily dosing, in a package containing 60 tablets. The label includes storage instructions, manufacturer information (Prinston Laboratories), and distributor details (Solco Healthcare US, LLC). The Rx only designation and National Drug Code (NDC) 43547-346-06 are shown, along with a barcode and a non-coating area indication.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.